Clinical Report: Metformin and AMD: Signal or Noise?

Overview

A population-based study found that metformin use was associated with a 37% lower incidence of intermediate age-related macular degeneration (AMD) over five years among patients with type 2 diabetes. The study utilized systematic retinal image grading, providing a more accurate assessment compared to previous studies relying on administrative data.

Background

Age-related macular degeneration (AMD) is a leading cause of vision loss, particularly in older adults. Understanding potential protective factors, such as metformin, is crucial given the increasing prevalence of type 2 diabetes and its associated complications. This study adds to the growing body of literature exploring the pleiotropic effects of metformin beyond glycemic control.

Data Highlights

Key Findings

• Metformin use was associated with a 37% lower incidence of intermediate AMD over five years.
• Baseline analysis included 2,545 patients with gradable retinal images.
• At baseline, 284 patients had early AMD, 90 had intermediate AMD, and 12 had late AMD.
• No significant association was found between metformin use and early AMD or progression to late AMD.
• The study's findings support the need for prospective clinical trials to evaluate metformin's role in AMD progression.

Clinical Implications

The findings suggest that metformin may offer protective benefits against the development of intermediate AMD in patients with type 2 diabetes. Clinicians should consider these potential benefits when managing diabetic patients, although further research is needed to establish causality.

Conclusion

This study highlights a potential association between metformin use and reduced incidence of intermediate AMD, warranting further investigation through clinical trials. The observational nature of the findings emphasizes the need for cautious interpretation.

Related Resources & Content

1. Sun et al., BMJ Open Ophthalmology, 2023 -- Metformin and incidence of age-related macular degeneration in people with diabetes: a population-based 5-year case-control study
2. Brain, 2023 -- Metformin may lower the risk of Alzheimer's disease by elevating soluble amyloid-β42 concentrations
3. Critical Care, 2023 -- Interpreting metformin safety: the importance of context, selection, and monitoring
4. AAO Age-Related Macular Degeneration Guideline Summary - Guideline Central, 2025
5. Metformin and the Development of Age-Related Macular Degeneration | Diabetes | JAMA Ophthalmology
6. European Radiology — Correspondence: "Evaluating the Ongoing Use of Metformin in Patients Undergoing Contrast Administration: Insights from a Systematic Review and Meta-Analysis
7. The Journal of Clinical Endocrinology & Metabolism — Metabolomic Analysis of Serum Biomarkers Linked to New Cases of Type 2 Diabetes Mellitus in the Multi-Ethnic Study of Atherosclerosis and the Rotterdam Study
8. Current guideline-based care for AMD
9. Potential Efficacy of Metformin for Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
10. METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial
11. Metformin and the Development of Age-Related Macular Degeneration | Diabetes | JAMA Ophthalmology | JAMA Network
12. Metformin and incidence of age-related macular degeneration in people with diabetes: a population-based 5-year case-control study - The University of Liverpool Repository